Blockchain Registration Transaction Record

PharmAla Biotech Achieves Milestones in Global MDMA Production and Research

PharmAla Biotech achieves significant milestones in Australia, including the domestic manufacturing of GMP LaNeo MDMA capsules. The company also successfully closed a non-brokered private placement, raising $750,000 for global patent rights and clinical trials.

The advancements made by PharmAla Biotech and Cortexa Pty. in Australia have significant implications for the global pharmaceutical landscape. The domestic manufacturing of GMP LaNeo MDMA capsules in Australia not only supports clinical trials and clinical use, but also strengthens the local psychedelic landscape. Additionally, the successful private placement funding will enable PharmAla to further develop and commercialize novel drugs, addressing the global shortage of clinical-grade MDMA and impacting patient treatments outside of clinical trials.